Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research report report published on Saturday. The brokerage issued a sell rating on the stock.

Several other equities research analysts have also issued reports on the stock. Stephens reissued an equal weight rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, April 4th. UBS Group restated a neutral rating and set a $63.50 price objective (up from $58.00) on shares of Catalent in a research report on Tuesday, February 6th. Royal Bank of Canada restated a sector perform rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, February 20th. Finally, Barclays increased their price target on Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a research note on Thursday, January 25th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $52.46.

Catalent Trading Down 0.8 %

Shares of CTLT stock opened at $55.85 on Friday. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 1.73. The company has a market cap of $10.11 billion, a price-to-earnings ratio of -8.21, a PEG ratio of 6.03 and a beta of 1.20. Catalent has a 1 year low of $31.45 and a 1 year high of $60.20. The firm has a fifty day moving average price of $56.61 and a 200-day moving average price of $48.85.

Catalent (NYSE:CTLT) last released its earnings results on Friday, February 9th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.22). The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. Catalent had a negative net margin of 29.91% and a negative return on equity of 2.43%. Catalent’s revenue for the quarter was down 10.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. As a group, equities analysts predict that Catalent will post 0.28 earnings per share for the current year.

Hedge Funds Weigh In On Catalent

A number of large investors have recently made changes to their positions in the company. Lindbrook Capital LLC boosted its holdings in Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after acquiring an additional 208 shares during the period. Gladius Capital Management LP purchased a new stake in shares of Catalent during the third quarter valued at $28,000. Exchange Traded Concepts LLC bought a new position in shares of Catalent in the third quarter worth about $31,000. GAMMA Investing LLC purchased a new position in Catalent in the 4th quarter worth about $33,000. Finally, Cary Street Partners Investment Advisory LLC lifted its holdings in Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after buying an additional 709 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.